市場調查報告書

血脂異常市場:2019-2025

Hyperlipidemia Drug Market 2019-2025

出版商 Orion Market Research Pvt Ltd 商品編碼 949570
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
血脂異常市場:2019-2025 Hyperlipidemia Drug Market 2019-2025
出版日期: 2020年06月12日內容資訊: 英文
簡介

在預測期內,估計全球血脂異常藥物市場的複合年增長率較低。膽固醇患者數量的增加推動了全球血脂異常藥物市場的發展。根據世界衛生組織,高膽固醇血症估計每年導致超過260萬人死亡。美國幾乎37.0%的成年人具有高LDL-C水平。儘管如此,只有不到50.0%的患者正在接受任何治療,並且大約33.0%的患者未達到正常的脂質水平。但是,降血脂藥的副作用限制了市場的增長。

全球血脂異常藥物市場按藥物類別細分。按藥物類別,市場為HMG-CoA還原□抑製劑(他汀類藥物),PCSK9抑製劑,膽固醇吸收抑製劑,纖維酸衍生物(貝特酸鹽),菸酸(菸酸),膽汁酸螯合劑(BAS),組合它被分類為療法。從地區上看,全球血脂異常市場分為北美,歐洲,亞太地區和其他國家。

本報告對全球血脂異常藥物市場進行了調查,提供了市場概況,按藥物類別和地區劃分的趨勢以及進入市場的公司概況。

內容

第1章報告概述

第2章市場概述和見解

  • 調查範圍
  • 分析師見解和當前市場趨勢

第3章競爭情況

  • 公司份額分析
  • 主要策略分析
  • 主要公司分析
    • 阿斯利康PLC
    • 諾華公司
    • Mylan N.V. 輝瑞公司(li)
    • Sanofi-Aventis S.A.

第4章市場決定因素

  • 動機
  • 抑制因子
  • 市場機會

第5章市場細分

  • 按藥物類別的全球血脂異常市場
    • HMG-CoA還原□抑製劑(他汀類)
    • PCSK9抑製劑
    • 膽固醇吸收抑製劑
    • 纖維酸衍生物(纖維狀)
    • 菸酸(菸酸)
    • 膽汁酸螯合劑(BAS)
    • 聯合療法
    • 其他

第6章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他
  • 其他地區

第7章公司簡介

  • Abbott Laboratories
  • Amgen, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Co.
  • 第一三共株式會社
  • Dr.Reddy's Laboratories, Ltd.
  • GlaxoSmithKline PLC
  • Ionis Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi-Aventis S.A.
  • Sun Pharmaceutical Industries, Ltd.
  • Teva Pharmaceutical Industries, Ltd.
目錄
Product Code: OMR2021889

Global Hyperlipidemia Drug Market Size, Share & Trends Analysis Report, By Drug Class (HMG-CoA Reductase Inhibitors (Statins), PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Fabric Acid Derivatives (Fibrates), Niacin (Nicotinic Acid), Bile Acid Sequestrants(BAS), Combination Therapy, and Others) and Forecast Period 2019-2025

The global hyperlipidemiadrug market is estimated to grow at a low CAGR during the forecast period.The increasing number of cholesterol patients is propelling the global hyperlipidemiadrug market. As per WHO, hypercholesterolemia is estimated to result in more than 2.6 million deaths each year. Almost 37.0% of adults in the US have high LDL-C levels. Yet, lesser than 50.0% of patients receive any form of treatment and approximately 33.0% of patients undergoing treatment are unable to achieve normal lipid levels.However, the side effects of hyperlipidemia drugs are restraining the growth of the market.

The global hyperlipidemia drug market is segmented based on the drug class. Based on the drug class the market is segmented into HMG-CoA reductase inhibitors (statins), PCSK9 inhibitors, cholesterol absorption inhibitors, fabric acid derivatives (fibrates), niacin (nicotinic acid), bile acid sequestrants(BAS), combination therapy and others.Geographically, theglobal hyperlipidemiadrug market is segmented based on the region including North America, Europe, Asia-Pacific, and the Rest of the world (RoW).

The major manufactures of the hyperlipidemiadrug includeAmgen Inc.,Bristol-Myers Squibb Co., Daiichi Sankyo Co., Ltd., Ionis Pharmaceuticals, Inc., Mylan N.V, GlaxoSmithKline PLC Pfizer, Inc.,Sanofi-Aventis S.A.,Merck & Co., Inc.,Dr.Reddy's Laboratories, Ltd. and others.These companies are continuously making efforts to provide innovative products in the market.For instance, in April 2019, TtheUS FDA also approved Sanofi's Praluent. It is used as an adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce LDL-C.

Research Methodology

The market study of the global hyperlipidemiadrug market is incorporated by extensive primary and secondary research conducted by a research team. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

  • Reports of companies involved in the market
  • Authentic Public Databases
  • Whitepapers such as research papers and news blogs
  • Company websites and their product catalog

The report is intended for providers, suppliers, and distributors of hyperlipidemia drugs, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and will serve as a source for 360-degree analysis of the market.

Market Segmentation-

  • Global HyperlipidemiaDrugs Market Research and Analysis by Drug Class

The Report Covers:

  • Comprehensive research methodology of the global hyperlipidemiadrug market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Insights about market determinants which are stimulating the global hyperlipidemiadrug market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusions

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. AstraZeneca PLC
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Novartis AG
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Mylan N.V.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Pfizer, Inc.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Sanofi-Aventis S.A.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Hyperlipidemia Drug Marketby Drug Class
    • 5.1.1. HMG-CoA Reductase Inhibitors (Statins)
    • 5.1.2. PCSK9 Inhibitors
    • 5.1.3. Cholesterol Absorption Inhibitors
    • 5.1.4. Fabric Acid Derivatives (Fibrates)
    • 5.1.5. Niacin (Nicotinic Acid)
    • 5.1.6. Bile Acid Sequestrants(BAS)
    • 5.1.7. Combination Therapy
    • 5.1.8. Others

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. Amgen, Inc.
  • 7.3. AstraZeneca PLC
  • 7.4. Bristol-Myers Squibb Co.
  • 7.5. Daiichi Sankyo Co., Ltd.
  • 7.6. Dr.Reddy's Laboratories, Ltd.
  • 7.7. GlaxoSmithKline PLC
  • 7.8. Ionis Pharmaceuticals, Inc.
  • 7.9. Merck & Co., Inc.
  • 7.10. Mylan N.V.
  • 7.11. Novartis AG
  • 7.12. Pfizer, Inc.
  • 7.13. Sanofi-Aventis S.A.
  • 7.14. Sun Pharmaceutical Industries, Ltd.
  • 7.15. Teva Pharmaceutical Industries, Ltd.

LIST OF TABLES

  • 1. GLOBAL HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
  • 2. GLOBALHMG-COA REDUCTASE INHIBITORS (STATINS)MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 3. GLOBAL PCSK9 INHIBITORSMARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 4. GLOBAL CHOLESTEROL ABSORPTION INHIBITORSMARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 5. GLOBAL FABRIC ACID DERIVATIVES (FIBRATES)MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 6. GLOBAL NIACIN (NICOTINIC ACID)MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 7. GLOBAL BILE ACID SEQUESTRANTS(BAS)MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 8. GLOBAL COMBINATION THERAPYMARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 9. GLOBAL OTHERSHYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)
  • 10. GLOBAL HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 11. GLOBAL HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 12. NORTH AMERICAN HYPERLIPIDEMIADRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 13. NORTH AMERICAN HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
  • 14. EUROPEAN HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 15. EUROPEAN HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BYDRUG CLASS, 2018-2025 ($ MILLION)
  • 16. ASIA-PACIFIC HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 17. ASIA-PACIFIC HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY DRUGCLASS, 2018-2025 ($ MILLION)
  • 18. REST OF THE WORLD HYPERLIPIDEMIA DRUG MARKET RESEARCH AND ANALYSIS BY DRUGCLASS, 2018-2025 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL HYPERLIPIDEMIA DRUG MARKET SHARE BYDRUG CLASS, 2018 VS 2025 (%)
  • 2. GLOBAL HYPERLIPIDEMIA DRUG MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 3. US HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 4. CANADA HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 5. UK HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. FRANCE HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. GERMANY HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. ITALY HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. SPAIN HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. ROE HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. INDIA HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. CHINA HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. JAPAN HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. REST OF ASIA-PACIFIC HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. REST OF THE WORLD HYPERLIPIDEMIA DRUG MARKET SIZE, 2018-2025 ($ MILLION)